357 related articles for article (PubMed ID: 18674509)
21. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
22. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations.
Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ
Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
[TBL] [Abstract][Full Text] [Related]
24. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Plummer ER; Middleton MR; Jones C; Olsen A; Hickson I; McHugh P; Margison GP; McGown G; Thorncroft M; Watson AJ; Boddy AV; Calvert AH; Harris AL; Newell DR; Curtin NJ
Clin Cancer Res; 2005 May; 11(9):3402-9. PubMed ID: 15867241
[TBL] [Abstract][Full Text] [Related]
25. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
[TBL] [Abstract][Full Text] [Related]
26. PARP inhibitors attenuate chemotherapy-induced painful neuropathy.
Brederson JD; Joshi SK; Browman KE; Mikusa J; Zhong C; Gauvin D; Liu X; Shi Y; Penning TD; Shoemaker AR; Giranda VL
J Peripher Nerv Syst; 2012 Sep; 17(3):324-30. PubMed ID: 22971094
[TBL] [Abstract][Full Text] [Related]
27. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.
Wang B; Qian H; Yiu SM; Sun J; Zhu G
Eur J Med Chem; 2014 Jan; 71():366-73. PubMed ID: 24361480
[TBL] [Abstract][Full Text] [Related]
28. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
29. PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.
Herriott A; Tudhope SJ; Junge G; Rodrigues N; Patterson MJ; Woodhouse L; Lunec J; Hunter JE; Mulligan EA; Cole M; Allinson LM; Wallis JP; Marshall S; Wang E; Curtin NJ; Willmore E
Oncotarget; 2015 Dec; 6(41):43978-91. PubMed ID: 26539646
[TBL] [Abstract][Full Text] [Related]
30. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.
Drew Y; Plummer R
Drug Resist Updat; 2009 Dec; 12(6):153-6. PubMed ID: 19939726
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
Yang SX; Kummar S; Steinberg SM; Murgo AJ; Gutierrez M; Rubinstein L; Nguyen D; Kaur G; Chen AP; Giranda VL; Tomaszewski JE; Doroshow JH;
Cancer Biol Ther; 2009 Nov; 8(21):2004-9. PubMed ID: 19823047
[TBL] [Abstract][Full Text] [Related]
32. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.
Tentori L; Portarena I; Vernole P; De Fabritiis P; Madaio R; Balduzzi A; Roy R; Bonmassar E; Graziani G
Cancer Chemother Pharmacol; 2001 Apr; 47(4):361-9. PubMed ID: 11345654
[TBL] [Abstract][Full Text] [Related]
33. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.
Bowman KJ; White A; Golding BT; Griffin RJ; Curtin NJ
Br J Cancer; 1998 Nov; 78(10):1269-77. PubMed ID: 9823965
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.
Chen X; Huan X; Liu Q; Wang Y; He Q; Tan C; Chen Y; Ding J; Xu Y; Miao Z; Yang C
Eur J Med Chem; 2018 Feb; 145():389-403. PubMed ID: 29335205
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Tentori L; Leonetti C; Scarsella M; Muzi A; Mazzon E; Vergati M; Forini O; Lapidus R; Xu W; Dorio AS; Zhang J; Cuzzocrea S; Graziani G
FASEB J; 2006 Aug; 20(10):1709-11. PubMed ID: 16809434
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
Tentori L; Portarena I; Barbarino M; Balduzzi A; Levati L; Vergati M; Biroccio A; Gold B; Lombardi ML; Graziani G
Mol Pharmacol; 2003 Jan; 63(1):192-202. PubMed ID: 12488552
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
Russo AL; Kwon HC; Burgan WE; Carter D; Beam K; Weizheng X; Zhang J; Slusher BS; Chakravarti A; Tofilon PJ; Camphausen K
Clin Cancer Res; 2009 Jan; 15(2):607-12. PubMed ID: 19147766
[TBL] [Abstract][Full Text] [Related]
38. Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
Shibata H; Miuma S; Saldivar JC; Huebner K
Cancer Sci; 2011 Oct; 102(10):1882-8. PubMed ID: 21707865
[TBL] [Abstract][Full Text] [Related]
39. Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D-QSAR and docking.
Zeng H; Zhang H; Jang F; Zhao L; Zhang J
Chem Biol Drug Des; 2011 Sep; 78(3):333-52. PubMed ID: 21585709
[TBL] [Abstract][Full Text] [Related]
40. Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.
Penning TD; Zhu GD; Gong J; Thomas S; Gandhi VB; Liu X; Shi Y; Klinghofer V; Johnson EF; Park CH; Fry EH; Donawho CK; Frost DJ; Buchanan FG; Bukofzer GT; Rodriguez LE; Bontcheva-Diaz V; Bouska JJ; Osterling DJ; Olson AM; Marsh KC; Luo Y; Giranda VL
J Med Chem; 2010 Apr; 53(8):3142-53. PubMed ID: 20337371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]